#South Korea #Seoul #Ottimo Pharma #LOTTE BIOLOGICS #Antibody Therapies

LOTTE BIOLOGICS and Ottimo Pharma Collaboration

On June 19, 2025, LOTTE BIOLOGICS, a prominent player in the biopharmaceutical sector, announced a significant manufacturing partnership with Ottimo Pharma, a company specializing in cutting-edge antibody therapeutics. This strategic collaboration was formalized during an event at the Boston Convention and Exhibition Center as part of the BIO INTERNATIONAL 2025 conference.

The agreement focuses on the production of antibody drug substances for Ottimo Pharma’s flagship product, Jankistomig. This innovative therapy is designed to exploit dual pathways involving PD1 and VEGFR2, with the aim of improving the survival rates of cancer patients. The production will take place at LOTTE BIOLOGICS' state-of-the-art facility located in Syracuse, New York.

James Park, the CEO of LOTTE BIOLOGICS, expressed his excitement regarding the partnership, emphasizing the company's commitment to producing high-quality medicines that adhere to global standards. He stated, "This agreement serves as further validation of our competitiveness as a CDMO (Contract Development and Manufacturing Organization) in the global antibody therapeutics market."

Joseph Shultz, Vice President of Technical Development at Ottimo Pharma, also shared his optimism about the collaboration, pointing out that it represents a pivotal moment in their development process. He stated, "Partnering with Lotte's proven biomanufacturing capabilities enhances our operational readiness and supports our rapid path to IND (Investigational New Drug) submission and clinical trial initiation."

LOTTE BIOLOGICS has been expanding its influence in the biopharmaceutical industry through various partnerships with companies across Asia and Europe. Its dual production hubs in North America and Asia have positioned it well in the contract manufacturing sector, catering not only to antibody therapeutics but also to Antibody-Drug Conjugates (ADCs).

The current Syracuse Bio Campus offers a notable production capacity of 40,000 liters, equipped with eight 5,000-liter stainless steel bioreactors. In addition, the facility meets rigorous demands from over 62 regulatory agencies worldwide and complements LOTTE BIOLOGICS' extensive analytical and quality control testing laboratories. The company is also planning to establish Plant 1 at its Songdo Bio Campus in South Korea by 2027, which will feature an impressive capacity of 120,000 liters, allowing for the fulfillment of larger contracts on a global scale.

To enhance its service offerings, LOTTE BIOLOGICS has forged strategic alliances with various global Contract Development Organizations (CDOs) and drug product manufacturers (DP), facilitating a comprehensive approach to drug development that ranges from initial phases all the way to commercialization. This integrated service model is aimed at providing tailored solutions to clients.

LOTTE BIOLOGICS, founded in 2022 and headquartered in Seoul, South Korea, continues to invest substantially in its capabilities, particularly in ADC modalities, with over $100 million committed to developing both drug substance and conjugation services.

As the company looks to the future, the construction of additional bio plants in Songdo is set to further strengthen its manufacturing capabilities. These new facilities, each equipped with advanced bioreactor technology, will ultimately contribute to a substantial increase in production volume, supporting LOTTE BIOLOGICS' mission to deliver innovative and effective therapeutic solutions to a global market.

For more information about LOTTE BIOLOGICS and its projects, please visit www.lottebiologics.com.